Takeda, Lundbeck submit vortioxetine NDA to FDA
Vortioxetine is under investigation as an antidepressant with multimodal activity that is thought to work through receptor activity modulation and reuptake inhibition. Takeda Global Research & Development Center
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.